Skip to main content
SpringerLink
Log in

Oncologic Emergencies

  • Chapter
  • First Online:
Emergency Department Critical Care

Abstract

With the overall incidence of cancer rising worldwide, management of a diverse set of emergencies stemming from underlying malignancy is increasingly common in emergency departments and intensive care units. Diagnosis of these conditions is complicated by their often nonspecific presenting symptoms, particularly in the setting of a known malignancy that may also cause a similar clinical picture. Nonetheless, vigilance must be maintained as these emergencies can threaten life and limb, and may respond to specific therapies. Malignant pericardial disease, hypercalcemia of malignancy, tumor lysis syndrome, metastatic spinal cord compression, superior vena cava syndrome, and leukostasis are reviewed in this chapter. For each section, a corresponding box briefly summarizes presentation and management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Press OW, Livingston R. Management of malignant pericardial effusion and tamponade. JAMA. 1987;257:1088–92.

    CAS  PubMed  Google Scholar 

  2. Lestuzzi C. Neoplastic pericardial disease: old and current strategies for diagnosis and management. World J Cardiol. 2010;2:270–9.

    PubMed  PubMed Central  Google Scholar 

  3. Karam N, Patel P, deFilippi C. Diagnosis and management of chronic pericardial effusions. Am J Med Sci. 2001;322:79–87.

    CAS  PubMed  Google Scholar 

  4. Imazio M, Demichelis B, Parrini I, et al. Relation of acute pericardial disease to malignancy. Am J Cardiol. 2005;95:1393–4.

    PubMed  Google Scholar 

  5. Dragoescu EA, Liu L. Pericardial fluid cytology: an analysis of 128 specimens over a 6-year period. Cancer Cytopathol. 2013;121:242–51.

    CAS  PubMed  Google Scholar 

  6. Spodick DH. Acute cardiac tamponade. N Engl J Med. 2003;349:684–90.

    PubMed  Google Scholar 

  7. Imazio M, Adler Y. Management of pericardial effusion. Eur Heart J. 2013;34:1186–97.

    PubMed  Google Scholar 

  8. Wilkes JD, Fidias P, Vaickus L, Perez RP. Malignancy-related pericardial effusion. 127 cases from the Roswell Park Cancer Institute. Cancer. 1995;76:1377–87.

    CAS  PubMed  Google Scholar 

  9. Roy CL, Minor MA, Brookhart MA, Choudhry NK. Does this patient with a pericardial effusion have cardiac tamponade? JAMA. 2007;297:1810–8.

    CAS  PubMed  Google Scholar 

  10. Argulian E, Messerli F. Misconceptions and facts about pericardial effusion and tamponade. Am J Med. 2013;126:858–61.

    PubMed  Google Scholar 

  11. Cooper JP, Oliver RM, Currie P, Walker JM, Swanton RH. How do the clinical findings in patients with pericardial effusions influence the success of aspiration? Br Heart J. 1995;73:351–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Guberman BA, Fowler NO, Engel PJ, Gueron M, Allen JM. Cardiac tamponade in medical patients. Circulation. 1981;64:633–40.

    CAS  PubMed  Google Scholar 

  13. Argulian E, Herzog E, Halpern DG, Messerli FH. Paradoxical hypertension with cardiac tamponade. Am J Cardiol. 2012;110:1066–9.

    PubMed  Google Scholar 

  14. Imazio M, Spodick DH, Brucato A, Trinchero R, Adler Y. Controversial issues in the management of pericardial diseases. Circulation. 2010;121:916–28.

    PubMed  Google Scholar 

  15. Karatolios K, Pankuweit S, Maisch B. Diagnostic value of biochemical biomarkers in malignant and non-malignant pericardial effusion. Heart Fail Rev. 2013;18:337–44.

    CAS  PubMed  Google Scholar 

  16. McCurdy MT, Shanholtz CB. Oncologic emergencies. Crit Care Med. 2012;40:2212–22.

    PubMed  Google Scholar 

  17. Tsang TS, Enriquez-Sarano M, Freeman WK, et al. Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: clinical profile, practice patterns, and outcomes spanning 21 years. Mayo Clin Proc. 2002;77:429–36.

    PubMed  Google Scholar 

  18. Maggiolini S, Bozzano A, Russo P, et al. Echocardiography-guided pericardiocentesis with probe-mounted needle: report of 53 cases. J Am Soc Echocardiogr. 2001;14:821–4.

    CAS  PubMed  Google Scholar 

  19. Gascho JA, Martins JB, Marcus ML, Kerber RE. Effects of volume expansion and vasodilators in acute pericardial tamponade. Am J Physiol. 1981;240:H49–53.

    CAS  PubMed  Google Scholar 

  20. Martins JB, Manuel WJ, Marcus ML, Kerber RE. Comparative effects of catecholamines in cardiac tamponade: experimental and clinical studies. Am J Cardiol. 1980;46:59–66.

    CAS  PubMed  Google Scholar 

  21. Celik S, Lestuzzi C, Cervesato E, et al. Systemic chemotherapy in combination with pericardial window has better outcomes in malignant pericardial effusions. J Thorac Cardiovasc Surg. 2014;148:2288–93.

    PubMed  Google Scholar 

  22. Lestuzzi C, Bearz A, Lafaras C, et al. Neoplastic pericardial disease in lung cancer: impact on outcomes of different treatment strategies. A multicenter study. Lung Cancer. 2011;72:340–7.

    PubMed  Google Scholar 

  23. Saltzman AJ, Paz YE, Rene AG, et al. Comparison of surgical pericardial drainage with percutaneous catheter drainage for pericardial effusion. J Invasive Cardiol. 2012;24:590–3.

    PubMed  PubMed Central  Google Scholar 

  24. Lindner G, Felber R, Schwarz C, et al. Hypercalcemia in the ED: prevalence, etiology, and outcome. Am J Emerg Med. 2013;31:657–60.

    PubMed  Google Scholar 

  25. Behl D, Hendrickson AW, Moynihan TJ. Oncologic emergencies. Crit Care Clin. 2010;26:181–205.

    CAS  PubMed  Google Scholar 

  26. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005;352:373–9.

    CAS  PubMed  Google Scholar 

  27. Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT. Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med. 1990;112:499–504.

    CAS  PubMed  Google Scholar 

  28. Zhang SJ, Hu Y, Cao J, et al. Analysis on survival and prognostic factors for cancer patients with malignancy-associated hypercalcemia. Asian Pac J Cancer Prev. 2013;14:6715–9.

    Google Scholar 

  29. Sargent JT, Smith OP. Haematological emergencies managing hypercalcaemia in adults and children with haematological disorders. Br J Haematol. 2010;149:465–77.

    CAS  PubMed  Google Scholar 

  30. Reagan P, Pani A, Rosner MH. Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy. Am J Kidney Dis. 2014;63:141–7.

    PubMed  Google Scholar 

  31. Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin’s disease and non-Hodgkin’s lymphomas. Blood. 1993;82:1383–94.

    CAS  PubMed  Google Scholar 

  32. Bilezikian JP. Management of acute hypercalcemia. N Engl J Med. 1992;326:1196–203.

    CAS  PubMed  Google Scholar 

  33. Bellon M, Ko NL, Lee MJ, et al. Adult T-cell leukemia cells overexpress Wnt5a and promote osteoclast differentiation. Blood. 2013;121:5045–54.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Moseley JM, Kubota M, Diefenbach-Jagger H, et al. Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc Natl Acad Sci U S A. 1987;84:5048–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Jacobs TP, Bilezikian JP. Clinical review: rare causes of hypercalcemia. J Clin Endocrinol Metab. 2005;90:6316–22.

    CAS  PubMed  Google Scholar 

  36. Davies M, Hayes ME, Yin JA, Berry JL, Mawer EB. Abnormal synthesis of 1,25-dihydroxyvitamin D in patients with malignant lymphoma. J Clin Endocrinol Metab. 1994;78:1202–7.

    CAS  PubMed  Google Scholar 

  37. Mudde AH, van den Berg H, Boshuis PG, et al. Ectopic production of 1,25-dihydroxyvitamin D by B-cell lymphoma as a cause of hypercalcemia. Cancer. 1987;59:1543–6.

    CAS  PubMed  Google Scholar 

  38. Yoshimoto K, Yamasaki R, Sakai H, et al. Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia. J Clin Endocrinol Metab. 1989;68:976–81.

    CAS  PubMed  Google Scholar 

  39. Nussbaum SR, Gaz RD, Arnold A. Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N Engl J Med. 1990;323:1324–8.

    CAS  PubMed  Google Scholar 

  40. Doyle MA, Malcolm JC. An unusual case of malignancy-related hypercalcemia. Int J Gen Med. 2013;7:21–7.

    PubMed  PubMed Central  Google Scholar 

  41. Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG. Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia. Lancet. 1992;339:164–7.

    CAS  PubMed  Google Scholar 

  42. Rizzoli R, Thiebaud D, Bundred N, et al. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. J Clin Endocrinol Metab. 1999;84:3545–50.

    CAS  PubMed  Google Scholar 

  43. Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocana A, Stewart AF. Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab. 2003;88:1603–9.

    CAS  PubMed  Google Scholar 

  44. Nakajima N, Ueda M, Nagayama H, Yamazaki M, Katayama Y. Posterior reversible encephalopathy syndrome due to hypercalcemia associated with parathyroid hormone-related peptide: a case report and review of the literature. Intern Med. 2013;52:2465–8.

    PubMed  Google Scholar 

  45. Ladenson JH, Lewis JW, Boyd JC. Failure of total calcium corrected for protein, albumin, and pH to correctly assess free calcium status. J Clin Endocrinol Metab. 1978;46:986–93.

    CAS  PubMed  Google Scholar 

  46. Slomp J, van der Voort PH, Gerritsen RT, Berk JA, Bakker AJ. Albumin-adjusted calcium is not suitable for diagnosis of hyper- and hypocalcemia in the critically ill. Crit Care Med. 2003;31:1389–93.

    CAS  PubMed  Google Scholar 

  47. Fritchie K, Zedek D, Grenache DG. The clinical utility of parathyroid hormone-related peptide in the assessment of hypercalcemia. Clin Chim Acta. 2009;402:146–9.

    CAS  PubMed  Google Scholar 

  48. Wimalawansa SJ. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. Cancer. 1994;73:2223–30.

    CAS  PubMed  Google Scholar 

  49. Milionis HJ, Rizos E, Liamis G, Nikas S, Siamopoulos KC, Elisaf MS. Acid-base and electrolyte disturbances in patients with hypercalcemia. South Med J. 2002;95:1280–7.

    PubMed  Google Scholar 

  50. Soyfoo MS, Brenner K, Paesmans M, Body JJ. Non-malignant causes of hypercalcemia in cancer patients: a frequent and neglected occurrence. Support Care Cancer. 2013;21:1415–9.

    CAS  PubMed  Google Scholar 

  51. LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med. 2008;149:259–63.

    PubMed  Google Scholar 

  52. Layman R, Olson K, Van Poznak C. Bisphosphonates for breast cancer: questions answered, questions remaining. Hematol Oncol Clin North Am. 2007;21:341–67.

    PubMed  Google Scholar 

  53. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19:558–67.

    CAS  PubMed  Google Scholar 

  54. Major PP, Coleman RE. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program. Semin Oncol. 2001;28:17–24.

    CAS  PubMed  Google Scholar 

  55. Nussbaum SR, Younger J, Vandepol CJ, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med. 1993;95:297–304.

    CAS  PubMed  Google Scholar 

  56. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83:1032–45.

    CAS  PubMed  Google Scholar 

  57. Silva OL, Becker KL. Salmon calcitonin in the treatment of hypercalcemia. Arch Intern Med. 1973;132:337–9.

    CAS  PubMed  Google Scholar 

  58. Hu MI, Glezerman IG, Leboulleux S, et al. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab. 2014;99:3144–52. https://doi.org/10.1210/jc.2014-1001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Hu MI, Glezerman I, Leboulleux S, et al. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. J Natl Cancer Inst. 2013;105:1417–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Boikos SA, Hammers HJ. Denosumab for the treatment of bisphosphonate-refractory hypercalcemia. J Clin Oncol. 2012;30:e299.

    PubMed  Google Scholar 

  61. Teng J, Abell S, Hicks RJ, et al. Protracted hypocalcaemia following a single dose of denosumab in humoral hypercalcaemia of malignancy due to PTHrP-secreting neuroendocrine tumour. Clin Endocrinol (Oxf). 2014;81:940.

    CAS  Google Scholar 

  62. Cvitkovic F, Armand JP, Tubiana-Hulin M, Rossi JF, Warrell RP Jr. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cancer J. 2006;12:47–53.

    CAS  PubMed  Google Scholar 

  63. Chisholm MA, Mulloy AL, Taylor AT. Acute management of cancer-related hypercalcemia. Ann Pharmacother. 1996;30:507–13.

    CAS  PubMed  Google Scholar 

  64. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990;112:352–64.

    CAS  PubMed  Google Scholar 

  65. Koo WS, Jeon DS, Ahn SJ, Kim YS, Yoon YS, Bang BK. Calcium-free hemodialysis for the management of hypercalcemia. Nephron. 1996;72:424–8.

    CAS  PubMed  Google Scholar 

  66. Hassan BA, Yusoff ZB, Hassali MA, Othman SB, Weiderpass E. Impact of chemotherapy on hypercalcemia in breast and lung cancer patients. Asian Pac J Cancer Prev. 2012;13:4373–8.

    PubMed  Google Scholar 

  67. Ipekci SH, Baldane S, Ozturk E, et al. Letrozole induced hypercalcemia in a patient with breast cancer. Case Rep Oncol Med. 2014;2014:608585.

    PubMed  PubMed Central  Google Scholar 

  68. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3–11.

    PubMed  Google Scholar 

  69. Koduri PR. Hyperphosphatemia and tumor lysis syndrome. Ann Hematol. 2005;84:696.

    PubMed  Google Scholar 

  70. Desmeules S, Bergeron MJ, Isenring P. Acute phosphate nephropathy and renal failure. N Engl J Med. 2003;349:1006–7.

    CAS  PubMed  Google Scholar 

  71. Shimada M, Johnson RJ, May WS Jr, et al. A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome. Nephrol Dial Transplant. 2009;24:2960–4.

    CAS  PubMed  Google Scholar 

  72. Wilson FP, Berns JS. Tumor lysis syndrome: new challenges and recent advances. Adv Chronic Kidney Dis. 2014;21:18–26.

    PubMed  PubMed Central  Google Scholar 

  73. Canet E, Zafrani L, Lambert J, et al. Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS One. 2013;8:e55870.

    CAS  PubMed  PubMed Central  Google Scholar 

  74. Darmon M, Guichard I, Vincent F, Schlemmer B, Azoulay E. Prognostic significance of acute renal injury in acute tumor lysis syndrome. Leuk Lymphoma. 2010;51:221–7.

    PubMed  Google Scholar 

  75. Cairo MS, Coiffier B, Reiter A, Younes A, TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149:578–86.

    CAS  PubMed  Google Scholar 

  76. McBride A, Westervelt P. Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies. J Hematol Oncol. 2012;5:75.

    PubMed  PubMed Central  Google Scholar 

  77. Duff DJ, Haddadin S, Freter C, Papageorgiou C. Gemcitabine and cisplatin-induced tumor lysis syndrome in a patient with gallbladder carcinoma: a case report. Oncol Lett. 2013;5:1237–9.

    PubMed  PubMed Central  Google Scholar 

  78. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26:2767–78.

    CAS  PubMed  Google Scholar 

  79. Hsu HH, Huang CC. Acute spontaneous tumor lysis in anaplastic large T-cell lymphoma presenting with hyperuricemic acute renal failure. Int J Hematol. 2004;79:48–51.

    PubMed  Google Scholar 

  80. Van Mieghem C, Sabbe M, Knockaert D. The clinical value of the ECG in noncardiac conditions. Chest. 2004;125:1561–76.

    PubMed  Google Scholar 

  81. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364:1844–54.

    CAS  PubMed  PubMed Central  Google Scholar 

  82. Kelton J, Kelley WN, Holmes EW. A rapid method for the diagnosis of acute uric acid nephropathy. Arch Intern Med. 1978;138:612–5.

    CAS  PubMed  Google Scholar 

  83. Tungsanga K, Boonwichit D, Lekhakula A, Sitprija V. Urine uric acid and urine creatine ratio in acute renal failure. Arch Intern Med. 1984;144:934–7.

    CAS  PubMed  Google Scholar 

  84. Ten Harkel AD, Kist-Van Holthe JE, Van Weel M, Van der Vorst MM. Alkalinization and the tumor lysis syndrome. Med Pediatr Oncol. 1998;31:27–8.

    PubMed  Google Scholar 

  85. Weisberg LS. Management of severe hyperkalemia. Crit Care Med. 2008;36:3246–51.

    PubMed  Google Scholar 

  86. Rogers FB, Li SC. Acute colonic necrosis associated with sodium polystyrene sulfonate (Kayexalate) enemas in a critically ill patient: case report and review of the literature. J Trauma. 2001;51:395–7.

    CAS  PubMed  Google Scholar 

  87. Coiffier B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin’s lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol. 2003;21:4402–6.

    CAS  PubMed  Google Scholar 

  88. Bosly A, Sonet A, Pinkerton CR, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer. 2003;98:1048–54.

    CAS  PubMed  Google Scholar 

  89. Bucklin MH, Groth CM. Mortality following rasburicase-induced methemoglobinemia. Ann Pharmacother. 2013;47:1353–8.

    PubMed  Google Scholar 

  90. Hummel M, Reiter S, Adam K, Hehlmann R, Buchheidt D. Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase. Eur J Haematol. 2008;80:331–6.

    CAS  PubMed  Google Scholar 

  91. Knoebel RW, Lo M, Crank CW. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome. J Oncol Pharm Pract. 2011;17:147–54.

    CAS  PubMed  Google Scholar 

  92. Vines AN, Shanholtz CB, Thompson JL. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients. Ann Pharmacother. 2010;44:1529–37.

    CAS  PubMed  Google Scholar 

  93. Trifilio S, Gordon L, Singhal S, et al. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant. 2006;37:997–1001.

    CAS  PubMed  Google Scholar 

  94. McDonnell AM, Lenz KL, Frei-Lahr DA, Hayslip J, Hall PD. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy. 2006;26:806–12.

    CAS  PubMed  Google Scholar 

  95. Montesinos P, Lorenzo I, Martin G, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica. 2008;93:67–74.

    CAS  PubMed  Google Scholar 

  96. Byrne TN. Spinal cord compression from epidural metastases. N Engl J Med. 1992;327:614–9.

    CAS  PubMed  Google Scholar 

  97. Loblaw DA, Laperriere NJ, Mackillop WJ. A population-based study of malignant spinal cord compression in Ontario. Clin Oncol. 2003;15:211–7.

    CAS  Google Scholar 

  98. Sansur CA, Pouratian N, Dumont AS, Schiff D, Shaffrey CI, Shaffrey ME. Part II: spinal-cord neoplasms--primary tumours of the bony spine and adjacent soft tissues. Lancet Oncol. 2007;8:137–47.

    PubMed  Google Scholar 

  99. Arguello F, Baggs RB, Duerst RE, Johnstone L, McQueen K, Frantz CN. Pathogenesis of vertebral metastasis and epidural spinal cord compression. Cancer. 1990;65:98–106.

    CAS  PubMed  Google Scholar 

  100. Traul DE, Shaffrey ME, Schiff D. Part I: spinal-cord neoplasms-intradural neoplasms. Lancet Oncol. 2007;8:35–45.

    PubMed  Google Scholar 

  101. Cole JS, Patchell RA. Metastatic epidural spinal cord compression. Lancet Neurol. 2008;7:459–66.

    PubMed  Google Scholar 

  102. Constans JP, de Divitiis E, Donzelli R, Spaziante R, Meder JF, Haye C. Spinal metastases with neurological manifestations. Review of 600 cases. J Neurosurg. 1983;59:111–8.

    CAS  PubMed  Google Scholar 

  103. Helweg-Larsen S, Hansen SW, Sorensen PS. Second occurrence of symptomatic metastatic spinal cord compression and findings of multiple spinal epidural metastases. Int J Radiat Oncol Biol Phys. 1995;33:595–8.

    CAS  PubMed  Google Scholar 

  104. Cook AM, Lau TN, Tomlinson MJ, Vaidya M, Wakeley CJ, Goddard P. Magnetic resonance imaging of the whole spine in suspected malignant spinal cord compression: impact on management. Clin Oncol. 1998;10:39–43.

    CAS  Google Scholar 

  105. van der Sande JJ, Kroger R, Boogerd W. Multiple spinal epidural metastases; an unexpectedly frequent finding. J Neurol Neurosurg Psychiatry. 1990;53:1001–3.

    PubMed  PubMed Central  Google Scholar 

  106. Helweg-Larsen S, Sorensen PS. Symptoms and signs in metastatic spinal cord compression: a study of progression from first symptom until diagnosis in 153 patients. Eur J Cancer. 1994;30A:396–8.

    CAS  PubMed  Google Scholar 

  107. Gilbert RW, Kim JH, Posner JB. Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Ann Neurol. 1978;3:40–51.

    CAS  PubMed  Google Scholar 

  108. Levack P, Graham J, Collie D, et al. Don’t wait for a sensory level--listen to the symptoms: a prospective audit of the delays in diagnosis of malignant cord compression. Clin Oncol. 2002;14:472–80.

    CAS  Google Scholar 

  109. Husband DJ. Malignant spinal cord compression: prospective study of delays in referral and treatment. BMJ. 1998;317:18–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  110. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268:760–5.

    CAS  PubMed  Google Scholar 

  111. Schiff D, O’Neill BP, Suman VJ. Spinal epidural metastasis as the initial manifestation of malignancy: clinical features and diagnostic approach. Neurology. 1997;49:452–6.

    CAS  PubMed  Google Scholar 

  112. Bayley A, Milosevic M, Blend R, et al. A prospective study of factors predicting clinically occult spinal cord compression in patients with metastatic prostate carcinoma. Cancer. 2001;92:303–10.

    CAS  PubMed  Google Scholar 

  113. Li KC, Poon PY. Sensitivity and specificity of MRI in detecting malignant spinal cord compression and in distinguishing malignant from benign compression fractures of vertebrae. Magn Reson Imaging. 1988;6:547–56.

    CAS  PubMed  Google Scholar 

  114. Husband DJ, Grant KA, Romaniuk CS. MRI in the diagnosis and treatment of suspected malignant spinal cord compression. Br J Radiol. 2001;74:15–23.

    CAS  PubMed  Google Scholar 

  115. Colletti PM, Siegel HJ, Woo MY, Young HY, Terk MR. The impact on treatment planning of MRI of the spine in patients suspected of vertebral metastasis: an efficacy study. Comput Med Imaging Graph. 1996;20:159–62.

    CAS  PubMed  Google Scholar 

  116. Schiff D, O’Neill BP, Wang CH, O’Fallon JR. Neuroimaging and treatment implications of patients with multiple epidural spinal metastases. Cancer. 1998;83:1593–601.

    CAS  PubMed  Google Scholar 

  117. Portenoy RK, Galer BS, Salamon O, et al. Identification of epidural neoplasm. Radiography and bone scintigraphy in the symptomatic and asymptomatic spine. Cancer. 1989;64:2207–13.

    CAS  PubMed  Google Scholar 

  118. O’Rourke T, George CB, Redmond J 3rd, et al. Spinal computed tomography and computed tomographic metrizamide myelography in the early diagnosis of metastatic disease. J Clin Oncol. 1986;4:576–83.

    PubMed  Google Scholar 

  119. Rodichok LD, Harper GR, Ruckdeschel JC, et al. Early diagnosis of spinal epidural metastases. Am J Med. 1981;70:1181–8.

    CAS  PubMed  Google Scholar 

  120. Gosfield E 3rd, Alavi A, Kneeland B. Comparison of radionuclide bone scans and magnetic resonance imaging in detecting spinal metastases. J Nucl Med. 1993;34:2191–8.

    PubMed  Google Scholar 

  121. Hagenau C, Grosh W, Currie M, Wiley RG. Comparison of spinal magnetic resonance imaging and myelography in cancer patients. J Clin Oncol. 1987;5:1663–9.

    CAS  PubMed  Google Scholar 

  122. Carmody RF, Yang PJ, Seeley GW, Seeger JF, Unger EC, Johnson JE. Spinal cord compression due to metastatic disease: diagnosis with MR imaging versus myelography. Radiology. 1989;173:225–9.

    CAS  PubMed  Google Scholar 

  123. Helweg-Larsen S. Clinical outcome in metastatic spinal cord compression. A prospective study of 153 patients. Acta Neurol Scand. 1996;94:269–75.

    CAS  PubMed  Google Scholar 

  124. Sorensen S, Helweg-Larsen S, Mouridsen H, Hansen HH. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer. 1994;30A:22–7.

    CAS  PubMed  Google Scholar 

  125. Greenberg HS, Kim JH, Posner JB. Epidural spinal cord compression from metastatic tumor: results with a new treatment protocol. Ann Neurol. 1980;8:361–6.

    CAS  PubMed  Google Scholar 

  126. Vecht CJ, Haaxma-Reiche H, van Putten WL, de Visser M, Vries EP, Twijnstra A. Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal cord compression. Neurology. 1989;39:1255–7.

    CAS  PubMed  Google Scholar 

  127. Loblaw DA, Mitera G, Ford M, Laperriere NJ. A 2011 updated systematic review and clinical practice guideline for the management of malignant extradural spinal cord compression. Int J Radiat Oncol Biol Phys. 2012;84:312–7.

    PubMed  Google Scholar 

  128. Maranzano E, Latini P, Beneventi S, et al. Radiotherapy without steroids in selected metastatic spinal cord compression patients. A phase II trial. Am J Clin Oncol. 1996;19:179–83.

    CAS  PubMed  Google Scholar 

  129. Prasad D, Schiff D. Malignant spinal-cord compression. Lancet Oncol. 2005;6:15–24.

    PubMed  Google Scholar 

  130. Young RF, Post EM, King GA. Treatment of spinal epidural metastases. Randomized prospective comparison of laminectomy and radiotherapy. J Neurosurg. 1980;53:741–8.

    CAS  PubMed  Google Scholar 

  131. Sorensen S, Borgesen SE, Rohde K, et al. Metastatic epidural spinal cord compression. Results of treatment and survival. Cancer. 1990;65:1502–8.

    CAS  PubMed  Google Scholar 

  132. Findlay GF. Adverse effects of the management of malignant spinal cord compression. J Neurol Neurosurg Psychiatry. 1984;47:761–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  133. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005;366:643–8.

    PubMed  Google Scholar 

  134. Bach F, Agerlin N, Sorensen JB, et al. Metastatic spinal cord compression secondary to lung cancer. J Clin Oncol. 1992;10:1781–7.

    CAS  PubMed  Google Scholar 

  135. Rades D, Huttenlocher S, Bajrovic A, et al. Surgery followed by radiotherapy versus radiotherapy alone for metastatic spinal cord compression from unfavorable tumors. Int J Radiat Oncol Biol Phys. 2011;81:e861–8.

    PubMed  Google Scholar 

  136. Klimo P Jr, Thompson CJ, Kestle JR, Schmidt MH. A meta-analysis of surgery versus conventional radiotherapy for the treatment of metastatic spinal epidural disease. Neuro Oncol. 2005;7:64–76.

    PubMed  PubMed Central  Google Scholar 

  137. Rades D, Huttenlocher S, Dunst J, et al. Matched pair analysis comparing surgery followed by radiotherapy and radiotherapy alone for metastatic spinal cord compression. J Clin Oncol. 2010;28:3597–604.

    PubMed  Google Scholar 

  138. Loblaw DA, Perry J, Chambers A, Laperriere NJ. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative’s Neuro-Oncology Disease Site Group. J Clin Oncol. 2005;23:2028–37.

    PubMed  Google Scholar 

  139. Ghogawala Z, Mansfield FL, Borges LF. Spinal radiation before surgical decompression adversely affects outcomes of surgery for symptomatic metastatic spinal cord compression. Spine. 2001;26:818–24.

    CAS  PubMed  Google Scholar 

  140. Holt T, Hoskin P, Maranzano E, et al. Malignant epidural spinal cord compression: the role of external beam radiotherapy. Curr Opin Support Palliat Care. 2012;6:103–8.

    PubMed  Google Scholar 

  141. Maranzano E, Trippa F, Casale M, et al. 8Gy single-dose radiotherapy is effective in metastatic spinal cord compression: results of a phase III randomized multicentre Italian trial. Radiother Oncol. 2009;93:174–9.

    PubMed  Google Scholar 

  142. Maranzano E, Bellavita R, Rossi R, et al. Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial. J Clin Oncol. 2005;23:3358–65.

    PubMed  Google Scholar 

  143. Rades D, Stalpers LJ, Veninga T, et al. Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol. 2005;23:3366–75.

    PubMed  Google Scholar 

  144. Rades D, Walz J, Stalpers LJ, et al. Short-course radiotherapy (RT) for metastatic spinal cord compression (MSCC) due to renal cell carcinoma: results of a retrospective multi-center study. Eur Urol. 2006;49:846–52; discussion 52.

    PubMed  Google Scholar 

  145. Rades D, Fehlauer F, Veninga T, et al. Functional outcome and survival after radiotherapy of metastatic spinal cord compression in patients with cancer of unknown primary. Int J Radiat Oncol Biol Phys. 2007;67:532–7.

    PubMed  Google Scholar 

  146. Rades D, Lange M, Veninga T, et al. Final results of a prospective study comparing the local control of short-course and long-course radiotherapy for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys. 2011;79:524–30.

    PubMed  Google Scholar 

  147. Rades D, Fehlauer F, Schulte R, et al. Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. J Clin Oncol. 2006;24:3388–93.

    PubMed  Google Scholar 

  148. van der Sande JJ, Boogerd W, Kroger R, Kappelle AC. Recurrent spinal epidural metastases: a prospective study with a complete follow up. J Neurol Neurosurg Psychiatry. 1999;66:623–7.

    PubMed  PubMed Central  Google Scholar 

  149. Maranzano E, Trippa F, Casale M, Anselmo P, Rossi R. Reirradiation of metastatic spinal cord compression: definitive results of two randomized trials. Radiother Oncol. 2011;98:234–7.

    PubMed  Google Scholar 

  150. Nieder C, Grosu AL, Andratschke NH, Molls M. Update of human spinal cord reirradiation tolerance based on additional data from 38 patients. Int J Radiat Oncol Biol Phys. 2006;66:1446–9.

    PubMed  Google Scholar 

  151. Wang XS, Rhines LD, Shiu AS, et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1–2 trial. Lancet Oncol. 2012;13:395–402.

    PubMed  PubMed Central  Google Scholar 

  152. Ryu S, Rock J, Jain R, et al. Radiosurgical decompression of metastatic epidural compression. Cancer. 2010;116:2250–7.

    PubMed  Google Scholar 

  153. Maranzano E, Latini P, Checcaglini F, et al. Radiation therapy in metastatic spinal cord compression. A prospective analysis of 105 consecutive patients. Cancer. 1991;67:1311–7.

    CAS  PubMed  Google Scholar 

  154. Maranzano E, Latini P. Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial. Int J Radiat Oncol Biol Phys. 1995;32:959–67.

    CAS  PubMed  Google Scholar 

  155. Helweg-Larsen S, Sorensen PS, Kreiner S. Prognostic factors in metastatic spinal cord compression: a prospective study using multivariate analysis of variables influencing survival and gait function in 153 patients. Int J Radiat Oncol Biol Phys. 2000;46:1163–9.

    CAS  PubMed  Google Scholar 

  156. Sioutos PJ, Arbit E, Meshulam CF, Galicich JH. Spinal metastases from solid tumors. Analysis of factors affecting survival. Cancer. 1995;76:1453–9.

    CAS  PubMed  Google Scholar 

  157. Rades D, Douglas S, Huttenlocher S, et al. Validation of a score predicting post-treatment ambulatory status after radiotherapy for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys. 2011;79:1503–6.

    PubMed  Google Scholar 

  158. Rades D, Blach M, Bremer M, Wildfang I, Karstens JH, Heidenreich F. Prognostic significance of the time of developing motor deficits before radiation therapy in metastatic spinal cord compression: one-year results of a prospective trial. Int J Radiat Oncol Biol Phys. 2000;48:1403–8.

    CAS  PubMed  Google Scholar 

  159. Rades D, Heidenreich F, Karstens JH. Final results of a prospective study of the prognostic value of the time to develop motor deficits before irradiation in metastatic spinal cord compression. Int J Radiat Oncol Biol Phys. 2002;53:975–9.

    PubMed  Google Scholar 

  160. Abner A. Approach to the patient who presents with superior vena cava obstruction. Chest. 1993;103:394S–7S.

    CAS  PubMed  Google Scholar 

  161. Wilson LD, Detterbeck FC, Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med. 2007;356:1862–9.

    CAS  PubMed  Google Scholar 

  162. Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: clinical characteristics and evolving etiology. Medicine. 2006;85:37–42.

    PubMed  Google Scholar 

  163. Armstrong BA, Perez CA, Simpson JR, Hederman MA. Role of irradiation in the management of superior vena cava syndrome. Int J Radiat Oncol Biol Phys. 1987;13:531–9.

    CAS  PubMed  Google Scholar 

  164. de Jager CP, Rutten MJ, Lips DJ. “Benign” superior vena cava syndrome. Intensive Care Med. 2013;39:572–3.

    PubMed  Google Scholar 

  165. Shaikh I, Berg K, Kman N. Thrombogenic catheter-associated superior vena cava syndrome. Case Rep Emerg Med. 2013;2013:793054.

    PubMed  PubMed Central  Google Scholar 

  166. Shaheen K, Alraies MC. Superior vena cava syndrome. Cleve Clin J Med. 2012;79:410–2.

    PubMed  Google Scholar 

  167. Bechtold RE, Wolfman NT, Karstaedt N, Choplin RH. Superior vena caval obstruction: detection using CT. Radiology. 1985;157:485–7.

    CAS  PubMed  Google Scholar 

  168. Rice TW. Pleural effusions in superior vena cava syndrome: prevalence, characteristics, and proposed pathophysiology. Curr Opin Pulm Med. 2007;13:324–7.

    PubMed  Google Scholar 

  169. Jahangiri M, Goldstraw P. The role of mediastinoscopy in superior vena caval obstruction. Ann Thorac Surg. 1995;59:453–5.

    CAS  PubMed  Google Scholar 

  170. Mineo TC, Ambrogi V, Nofroni I, Pistolese C. Mediastinoscopy in superior vena cava obstruction: analysis of 80 consecutive patients. Ann Thorac Surg. 1999;68:223–6.

    CAS  PubMed  Google Scholar 

  171. Ahmann FR. A reassessment of the clinical implications of the superior vena caval syndrome. J Clin Oncol. 1984;2:961–9.

    CAS  PubMed  Google Scholar 

  172. Ferrari LR, Bedford RF. General anesthesia prior to treatment of anterior mediastinal masses in pediatric cancer patients. Anesthesiology. 1990;72:991–5.

    CAS  PubMed  Google Scholar 

  173. Jain R, Bansal D, Marwaha RK, Singhi S. Superior mediastinal syndrome: emergency management. Indian J Pediatr. 2013;80:55–9.

    PubMed  Google Scholar 

  174. Schraufnagel DE, Hill R, Leech JA, Pare JA. Superior vena caval obstruction. Is it a medical emergency? Am J Med. 1981;70:1169–74.

    CAS  PubMed  Google Scholar 

  175. Yu JB, Wilson LD, Detterbeck FC. Superior vena cava syndrome--a proposed classification system and algorithm for management. J Thorac Oncol. 2008;3:811–4.

    PubMed  Google Scholar 

  176. Juan YH, Saboo SS, Anand V, Chatzizisis YS, Lin YC, Steigner ML. Superior vena cava syndrome associated with right-to-left shunt through systemic-to-pulmonary venous collaterals. Korean J Radiol. 2014;15:185–7.

    PubMed  PubMed Central  Google Scholar 

  177. Kim HC, Chung JW, Park SH, et al. Systemic-to-pulmonary venous shunt in superior vena cava obstruction: depiction on computed tomography venography. Acta Radiol. 2004;45:269–74.

    CAS  PubMed  Google Scholar 

  178. Chan RH, Dar AR, Yu E, et al. Superior vena cava obstruction in small-cell lung cancer. Int J Radiat Oncol Biol Phys. 1997;38:513–20.

    CAS  PubMed  Google Scholar 

  179. Chan RC, Chan YC, Cheng SW. Mid- and long-term follow-up experience in patients with malignant superior vena cava obstruction. Interact Cardiovasc Thorac Surg. 2013;16:455–8.

    PubMed  PubMed Central  Google Scholar 

  180. Sobrinho G, Aguiar P. Stent placement for the treatment of malignant superior vena cava syndrome – a single-center series of 56 patients. Arch Bronconeumol. 2014;50:135–40.

    PubMed  Google Scholar 

  181. Marcy PY, Magne N, Bentolila F, Drouillard J, Bruneton JN, Descamps B. Superior vena cava obstruction: is stenting necessary? Support Care Cancer. 2001;9:103–7.

    CAS  PubMed  Google Scholar 

  182. Li H, Jiang X, Sun T. Open surgery repair for superior vena cava syndrome after failed endovascular stenting. Ann Thorac Surg. 2014;97:1445–7.

    PubMed  Google Scholar 

  183. Ganzel C, Becker J, Mintz PD, Lazarus HM, Rowe JM. Hyperleukocytosis, leukostasis and leukapheresis: practice management. Blood Rev. 2012;26:117–22.

    PubMed  Google Scholar 

  184. Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma. 2000;39:1–18.

    CAS  PubMed  Google Scholar 

  185. Stucki A, Rivier AS, Gikic M, Monai N, Schapira M, Spertini O. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood. 2001;97:2121–9.

    CAS  PubMed  Google Scholar 

  186. Mehta J, Singhal S. Hyperviscosity syndrome in plasma cell dyscrasias. Semin Thromb Hemost. 2003;29:467–71.

    PubMed  Google Scholar 

  187. Munoz J, Donthireddy V. CNS hyperleukocytosis. Blood. 2012;119:5953.

    PubMed  Google Scholar 

  188. Naunheim MR, Nahed BV, Walcott BP, et al. Diagnosis of acute lymphoblastic leukemia from intracerebral hemorrhage and blast crisis. A case report and review of the literature. Clin Neurol Neurosurg. 2010;112:575–7.

    PubMed  Google Scholar 

  189. Shiber JR, Fines RE. Cerebral hemorrhage due to hyperleukocytosis. J Emerg Med. 2011;40:674–7.

    PubMed  Google Scholar 

  190. Majhail NS, Lichtin AE. Acute leukemia with a very high leukocyte count: confronting a medical emergency. Cleve Clin J Med. 2004;71:633–7.

    PubMed  Google Scholar 

  191. Yen TH, Chang CT, Ng KK, Wu MS. Bilateral renal infarction in chronic myelomonocytic leukemia on blast crisis. Ren Fail. 2003;25:1029–35.

    PubMed  Google Scholar 

  192. Wu YK, Huang YC, Huang SF, Huang CC, Tsai YH. Acute respiratory distress syndrome caused by leukemic infiltration of the lung. J Formos Med Assoc. 2008;107:419–23.

    PubMed  Google Scholar 

  193. Jain R, Bansal D, Marwaha RK. Hyperleukocytosis: emergency management. Indian J Pediatr. 2013;80:144–8.

    PubMed  Google Scholar 

  194. Novotny JR, Muller-Beissenhirtz H, Herget-Rosenthal S, Kribben A, Duhrsen U. Grading of symptoms in hyperleukocytic leukaemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome. Eur J Haematol. 2005;74:501–10.

    CAS  PubMed  Google Scholar 

  195. Bug G, Anargyrou K, Tonn T, et al. Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis. Transfusion. 2007;47:1843–50.

    PubMed  Google Scholar 

  196. Oberoi S, Lehrnbecher T, Phillips B, et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. Leuk Res. 2014;38:460–8.

    PubMed  Google Scholar 

  197. De Santis GC, de Oliveira LC, Romano LG, et al. Therapeutic leukapheresis in patients with leukostasis secondary to acute myelogenous leukemia. J Clin Apher. 2011;26:181–5.

    PubMed  Google Scholar 

  198. Pastore F, Pastore A, Wittmann G, Hiddemann W, Spiekermann K. The role of therapeutic leukapheresis in hyperleukocytotic AML. PLoS One. 2014;9:e95062.

    PubMed  PubMed Central  Google Scholar 

  199. Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med. 2008;358:1362–9.

    CAS  PubMed  Google Scholar 

  200. Douglas S, Schild SE, Rades D. A new score predicting the survival of patients with spinal cord compression from myeloma. BMC Cancer. 2012;12:425.

    PubMed  PubMed Central  Google Scholar 

  201. Rades D, Veninga T, Stalpers LJ, et al. Prognostic factors predicting functional outcomes, recurrence-free survival, and overall survival after radiotherapy for metastatic spinal cord compression in breast cancer patients. Int J Radiat Oncol Biol Phys. 2006;64:182–8.

    PubMed  Google Scholar 

  202. Rades D, Douglas S, Veninga T, Schild SE. A validated survival score for patients with metastatic spinal cord compression from non-small cell lung cancer. BMC Cancer. 2012;12:302.

    PubMed  PubMed Central  Google Scholar 

  203. Douglas S, Huttenlocher S, Bajrovic A, Rudat V, Schild SE, Rades D. Prognostic factors for different outcomes in patients with metastatic spinal cord compression from cancer of unknown primary. BMC Cancer. 2012;12:261.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA

    David A. Wacker

  2. Departments of Medicine and Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD, USA

    Michael T. McCurdy

Authors
  1. David A. Wacker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael T. McCurdy
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. College of Medicine, University of Florida Health Science Center, Jacksonville, FL, USA

    Joseph R. Shiber

  2. Resuscitation & Emergency Critical Care, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Scott D. Weingart

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Wacker, D.A., McCurdy, M.T. (2020). Oncologic Emergencies. In: Shiber, J., Weingart, S. (eds) Emergency Department Critical Care. Springer, Cham. https://doi.org/10.1007/978-3-030-28794-8_29

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-28794-8_29

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-28792-4

  • Online ISBN: 978-3-030-28794-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation